

ASX Announcement

Orthocell Achieves First Sales of Remplir™ in the US\$84 million Thai Nerve Repair Market

- First commercial sales of Remplir™ have been achieved in the US\$84 million¹ Thai nerve repair market, marking another key milestone in Orthocell's Asian and global growth strategy.
- The sales follows Thai FDA approval and the appointment of Orthocell's exclusive in-country distributor MediTime, providing an established pathway to market through its existing customer relationships, dedicated clinical support capabilities and national coverage of leading hospitals.
- Orthocell is working directly with MediTime in country this week to coordinate the product launch, deliver comprehensive sales and product training, and engage prospective customers.
- Thailand's sophisticated healthcare market, well-developed hospital system and strong medical tourism sector make it a key market in Asia and an important component of the Company's global footprint.
- Remplir is now approved for sale and generating revenue in Australia, New Zealand, USA, Canada, Singapore, Hong Kong and Thailand, with expansion planned into the US\$750 million² EU/UK market following expected regulatory approval expected in 2H CY26.
- The Company remains well funded, with A\$44.1 million in available funds as at 30 June 2026 and no debt, supporting continued commercial expansion.

Perth, Australia; 21 September 2026: Regenerative medicine company Orthocell Limited (ASX: OCC, "Orthocell" or the "Company") is pleased to announce the first commercial sales of its transformative nerve repair product, Remplir™, in Thailand. The milestone extends Remplir's commercial presence in Asia and establishes a pathway into a strategically important market with a sophisticated healthcare system, significant market potential and a regional role in advanced surgical care.

The first sales mark a key milestone in Orthocell's Asian commercialisation strategy and follow the appointment of MediTime as the Company's exclusive in-country distributor for Remplir in Thailand.

MediTime is a specialist orthopaedics and sports medicine distributor with established coverage across leading hospitals, medical schools and regional centres in Thailand. They have built a strong commercial position in upper extremity orthopaedic surgery, providing direct access to Orthocell's core customer base of orthopaedic and plastic surgeons.

MediTime's model is underpinned by surgeon education and strong relationships with key opinion leaders, supporting both near-term adoption and long-term market development.

¹ Nerve repair market sizes estimated using reference papers from both US and OUS databases and studies.

² Nerve repair market sizes estimated using reference papers from both US and OUS databases and studies.

Orthocell's Commercial Director, Asia Pacific, Hamish Thrum, is supporting the Thai launch preparations and working closely with MediTime to train sales representatives and build surgeon engagement.

Orthocell Managing Director Paul Anderson said: "Achieving our first sales in Thailand marks an important milestone for Remplir in Asia and reflects the quality of the product, our supporting clinical data and our partnership with MediTime. Launch activities are well underway, with an initial focus on engaging surgeons, establishing accounts at key centres and building a strong foundation for adoption. While we expect sales volumes to be modest in the near term, we see significant potential for growth over the medium to longer term."

Orthocell will continue working closely with MediTime to build surgeon awareness, deliver clinical education and drive adoption of Remplir across Thailand. The launch strengthens the Company's commercial presence in Asia and advances its broader strategy to expand Remplir into key global nerve repair markets.

Release authorised by:

Paul Anderson

Orthocell Ltd CEO and MD

For more information, please contact:

General enquiries

Paul Anderson

Orthocell Limited
CEO and MD

P: +61 8 9360 2888

E: paul.anderson@orthocell.com

Media enquiries

Haley Chartres

H[^]CK Director

P: +61 423 139 163

E: haley@hck.digital

Investor enquiries

Shaun Duffy

VECTOR Advisors

P: +61 404 094 384

E: sduffy@vectoradvisors.au

About Orthocell Limited

ACN 118 897 135

Registered Office – Level 2, 161 Campus Drive, Murdoch University, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed a network of specialist US distributors and recorded initial sales. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand, Canada and Hong Kong. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @OrthocellLtd and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.